CESR s technical advice at level 2 on Risk Measurement for the purposes of the calculation of UCITS global exposure

Similar documents
Your ref., Your message of Our ref., person in charge Extension Date BSBV 64/ th July 2009 Dr. Rudorfer/Ob

V E R E I N I G U N G Ö S T E R R E I C H I S C H E R I N V E S T M E N T G E S E L L S C H A F T E N

1 Commodity Quay East Smithfield London, E1W 1AZ

INVESTMENT SERVICES RULES FOR RETAIL COLLECTIVE INVESTMENT SCHEMES

LYXOR ANSWER TO THE CONSULTATION PAPER "ESMA'S GUIDELINES ON ETFS AND OTHER UCITS ISSUES"

CESR s Guidelines on Risk Measurement and the Calculation of Global Exposure and Counterparty Risk for UCITS

ASSOSIM. Consultation paper - ESMA s guidelines on ETFs and other UCITS issue

ESMA guidelines on ETFs and other UCITS issues

UCITS Financial Derivative Instruments and Efficient Portfolio Management. November 2015

CESR's Advice on Clarification of Definitions concerning Eligible Assets for Investments of UCITS - 2 nd Consultation Paper

Chapter 1 Derivate Reporting. Chapter 2 Global Exposure

Undertakings for Collective Investment in Transferable Securities (UCITS) Financial Indices

Position AMF Recommendation Guide to the organisation of the risk management system within asset management companies DOC

Q&A. CSSF Circular 11/512. Issue 01. Luxembourg, 14 th November 2011

Position AMF Recommendation Guide to the organisation of the risk management system within asset management companies DOC

Guidance Note 2/07 Undertaking for Collective Investments in Transferable Securities (UCITS) Financial Indices. April 2008.

Morningstar s Response to ESMA s Consultation Paper on ETFs and Other UCITS Issues 9 March 2012

Regulatory Capital Disclosures Report. For the Quarterly Period Ended March 31, 2014

JAC Response to ESMA Consultation Paper on its guidelines for ETFs and other UCITS issues

AMF position ETFs and other UCITS issues

ESMA s policy orientations on guidelines for UCITS Exchange-Traded Funds and Structured UCITS

ESMA Consultation paper on the treatment of repurchase and reverse repurchase agreements.

Questions and Answers Risk Measurement and Calculation of Global Exposure and Counterparty Risk for UCITS

ESMA s new UCITS guidelines

BACKGROUND NOTE. Important Disclaimer

References: Articles to , to and of the AMF General Regulation

Amendments to the UCITS Notices and related Guidance Notes. December Consultation Paper CP31

CESR's guidelines concerning eligible assets for investment by UCITS

ESMA 103, rue de Grenelle Paris. Paris, March 30 th 2012

Market Risk Capital Disclosures Report. For the Quarterly Period Ended June 30, 2014

Questions and Answers ESMA s guidelines on ETFs and other UCITS issues

RESPONSES by the Commission de Surveillance du Secteur Financier ( CSSF ), Luxembourg to

UCITS VI Have your say

Final report. Revision of the provisions on diversification of collateral in ESMA s Guidelines on ETFs and other UCITS issues

FAX (+43-1)

SUBJECT: Change to compartment n 33 of the MULTI UNITS FRANCE SICAV (the SICAV ) indicated below: ISIN CODE

Box 1 (1)Do you consider there is a need to review the scope of assets and exposures that are deemed eligible for a UCITS fund?

Guidance consultation FSA REVIEWS OF CREDIT RISK MANAGEMENT BY CCPS. Financial Services Authority. July Dear Sirs

Questions and Answers ESMA s Guidelines on ETFs and other UCITS issues

Consultation on the adoption of ESMA s revised guidelines on ETFs and other UCITS issues. Consultation Paper CP84

STATUTORY INSTRUMENTS. S.I. No. 420 of 2015

RE: Modification of Sub-fund No. 31 of the MULTI UNITS FRANCE SICAV fund (the Fund ), indicated below:

TABULA EUROPEAN PERFORMANCE CREDIT UCITS ETF (EUR)

Q1 Do you consider there is a need to review the scope of assets and exposures that are deemed eligible for a UCITS fund?

For more information about H2O AM LLP, please visit

Challenges in Counterparty Credit Risk Modelling

EFAMA members strongly believe that the proposed calculation methodology by scenario is

GUIDELINES ON ETFs AND OTHER UCITS ISSUES

The PNC Financial Services Group, Inc. Basel III Pillar 3 Report: Standardized Approach June 30, 2018

The Irish Funds Industry Association responds to UCITS VI Consultation

The attention of investors is drawn to the "Risk Factors" section in the Section of the Prospectus entitled "The Company".

Questions and answers (Q&A) on the PRIIPs KID

GLOBAL HIGH INCOME BOND FUND

ING response to the draft Technical Standards for the Regulation on OTC Derivatives, CCPs and Trade Repositories

PRODUCT KEY FACTS. PIMCO FUNDS: GLOBAL INVESTORS SERIES PLC - Low Average Duration Fund. 10 April 2019

AXA WORLD FUNDS (the "Sicav") A Luxembourg Société d Investissement à Capital Variable

October Please note that we ask for our submission to remain private and therefore, not be made available for public inspection.

Guidance Note Capital Requirements Directive Financial derivatives, SFTs and long settlement transactions

Regulatory Capital Pillar 3 Disclosures

Questions and Answers. ESMA s guidelines on ETFs and other UCITS issues

Directive 2011/61/EU on Alternative Investment Fund Managers

In various tables, use of - indicates not meaningful or not applicable.

Derivatives Sound Practices for Federally Regulated Private Pension Plans

Derivative Contracts and Counterparty Risk

Natixis Asset Management Legal Department address:

COMMISSION DELEGATED REGULATION (EU) No /.. of XXX

Market Risk Disclosures For the Quarter Ended March 31, 2013

Sponsored by Scottrade Disclosure -

Market Risk Disclosures For the Quarterly Period Ended September 30, 2014

GLOBAL TOTAL RETURN BOND FUND. (the "Fund")

State of Texas Policies for Interest Rate Management Agreements

Book value (supervisory scope)

ANNEX B. Table of Contents

AGA - n 2931_09/Div. ESMA 103 Rue de Grenelle Paris

Official Journal of the European Union. (Non-legislative acts) REGULATIONS

What will Basel II mean for community banks? This

JPMORGAN ETFS (IRELAND) ICAV MANAGED FUTURES UCITS ETF. 10 July 2018

PRODUCT KEY FACTS HENDERSON HORIZON FUND PAN EUROPEAN PROPERTY EQUITIES FUND

Alternative Investment Management Association

Irish Funds Industry Association response to ESMA s policy orientations on guidelines for UCITS in Exchange-Traded Funds and Structured UCITS

CVA Capital Charges: A comparative analysis. November SOLUM FINANCIAL financial.com

Questions and Answers Application of the UCITS Directive

RBI/ /243 DBOD.No.BP.BC. 44 / / November 2, 2011

PARVEST REAL ESTATE SECURITIES PACIFIC ( Sub-fund )

FRAMEWORK FOR SUPERVISORY INFORMATION

Basel Committee on Banking Supervision. Basel III counterparty credit risk - Frequently asked questions

Re: Consultation paper ESMA s guidelines on ETFs and other UCITS issues (ESMA/2012/44)

Feedback Statement on CP84 Consultation on the adoption of ESMA s revised guidelines on ETFs and other UCITS issues

Basel II Pillar 3 disclosures 6M 09

Response to the Consultation Paper ESMA/2012/44: ESMA s guidelines on ETFs and other UCITS issues

The International Swaps and Derivatives Association ( ISDA ), and. The Association of Financial Markets in Europe ( AFME )

Collective Investment Schemes. Chapter 6. Operating duties and responsibilities

NOTICE FINANCIAL SERVICES BOARD. No. 2012

Opinion of the EBA on Good Practices for ETF Risk Management

What are the types of risk in a nonprofit portfolio?

Internal Trading Book Models Under Threat

From Financial Risk Management. Full book available for purchase here.

CRR IV - Article 194 CRR IV Principles governing the eligibility of credit risk mitigation techniques legal opinion

INVERCO REPLY TO ESMA DISCUSSION PAPER ON UCITS EXCHANGE-TRADED FUNDS AND STRUCTURED UCITS

Methods and conditions for reflecting the effects of credit risk mitigation techniques

Transcription:

INVESTMENT MANAGEMENT P.O. Box 90470, 2509 LL The Hague Department Risk Management Location Beatrixlaan 15 2595 AK The Hague The Netherlands Subject CESR s technical advice at level 2 on Risk Measurement for the purposes of the calculation of UCITS global exposure Date July 2 nd, 2009 Dear Sir, Madam, Please find herewith our response submitted as working document to your consultation. Best regards, Marc Spalburg Risk Manager Prinses Beatrixlaan 15, The Hague E marc.spalburg@ingim.com ING Investment Management (Europe) B.V., registered office The Hague Trade Register no. 27151163 The Hague

2/7 1 Do you agree with the proposed approach in relation to the calculation of global exposure? Agree to carve out counterparty risk from the calculation of global exposure. The text however mentions global exposure and total risk exposure indiscriminately in relation to the total net value of its portfolio. This leads to confusion and it is therefore suggested to consequently use only one term. It is suggested to name this economic exposure (instead of risk exposure) as the intention is to limit every 100 NAV invested to a maximum of 200 economic exposure (as the maximum leverage of economic exposure) as can be mimicked with the introduction of FDIs. 2 Should the counterparty risk involved in an OTC derivative be considered in the calculation of global exposure? No. no need as it is being measured, limited and managed in a different way. 3 Do you agree with the proposed approach or can you suggest an alternative approach? FDIs do two things: either they decrease economic exposure (hedging) or they increase economic exposure (investing, even if this entails a linear 1 on 1 look-a-like exposure replication). Therefore all FDIs to be included in the total economic/leverage exposure measure, not only the ones generating incremental exposure (note we disagree we the use of EPM in an economic exposure view, as EPM either increases or decreases economic exposure). 4 Do you agree that the incremental exposure/leverage generated through techniques such as repurchase and securities lending transactions should be included in the calculation of global exposure? We agree that when repurchase agreements or securities lending would/could (legally) lead to an effect on the level of leverage these need to be included in the measure of leverage. 5 Does option 1 correctly assess the market risk linked to investment in the corresponding instruments, and if so please explain?, as for both it reflects the maximum potential loss at t=0. 6 Does option 2 correctly assess the market risk linked to investment in the corresponding instruments, and if so please explain? for options, see comment under 5. No for CDS protection buyer, as delta is (as far as we know) not a relevant factor 7 Do you have any comments or other suggestions regarding other possible measurement approaches? The CDS protection buyer total commitment could be précised as the net

3/7 present value of the sum of the premiums instead of the sum of the premiums. The difference will be negligible in most cases. 8 Do you agree with the proposed approach, in particular the inclusion of a nonexhaustive list of financial derivatives? 9 Do you have any alternative suggestions for the conversion method? Always use maximum potential loss as the fall back if reliable conversions to replicated economic exposures can not be provided 10 Are there other types of financial derivative instruments which should be included in the paper? Inflation linked related derivatives Interest rate options P Notes 11 Are you aware of any type of financial derivative instrument where global exposure cannot be calculated using the commitment approach? Not at this moment 12 Do you agree with the approach regarding TRORS and derivatives with cash or an equivalent position?, as long as structure does not increase/decrease economic exposure (using [embedded] leverage], and for TRORS where the reference to the underlying notional is of the same value (equal and long only underlying) 13 Do you agree with the proposed use of the sensitivity approach? Not sure we understand the proposed description, we do see the intention 14 Do you consider that this should be compulsory for these types of derivative or optional for UCITS? No, either market value or worst potential loss 15 Do you agree with the analysis of the sensitivity approach described? Agree that interest rate instruments with longer maturity show more volatility than short dated instruments in general. This should however be expressed in the change in market value (equivalent economic exposure) as to measure leverage (in relation to the commitment approach). Tough we understand the intention we do not see how the proposed measures translate into the measure of leverage as described. 16 What quantitative level would you consider appropriate for the default sensitivity? The default sensitivity is already catered for in the pricing of the underlying 17 Do you have any additional comments or suggestions on this approach? No, either market value or worst potential loss seem to asses the true economic exposure best 18 Do you agree with the proposals regarding netting? in general 19 Do you have any additional comments and/or proposals?

4/7 What is meant with ALL in to demonstrate a strong and negative correlation in ALL market conditions? Correlations tend to go up in crisis instead of down. How is ALL to be proved? Which scenario should be tested and does/did liquidity allow this scenario to be executed in a true crisis? 20 Do you consider that hedging as described above should be permitted? 21 Do you consider that the strong correlation requirement should be further clarified by means of a quantitative threshold e.g. 0.9?, but probably -0.6 would suffice to start with 22 Can you suggest a possible threshold e.g. for the minimum correlation between stock baskets? Please justify your answer based on relevant market data. -0.6, not backed by relevant market data 23 Do you agree with this proposal? 24 Do you agree with this definition? Do you have any alternative suggestions? 25 Do you agree with the above approach? 26 What additional safeguards (if any) are necessary for UCITS which use VaR to calculate global exposure to ensure consistency with the total exposure limit of 200% of NAV? Capping and monitoring the daily VaR closely 27 Do you agree with the approach outlined in paragraphs 2.3, 2.4 and 2.5? 28 Do you have any comments or suggestions? To test the validity of the models throughout time and under different market circumstances data used as input should cover both recent volatilities, but also data from a complete multiyear economic cycle. Hence it is suggested to use (1) one set of 1 year of daily data to represent recent market movements and (2) one set of say 12 years of monthly data to span a longer economic cycle 29 Do you consider that VaR should be calculated at least daily? 30 What type of criteria should competent authorities take into account in an assessment of the VaR Models? -historical period considered as input -reliability of forecast when compared to (realized or hypothetical) PnL -comparing VaR method and asset type to determine best fit 31 Do you consider that VaR models should be approved by competent authorities? -, just as trading desk of banks are required to do 32 Is the proposed 3-step relative-var approach adequate to limit the global exposure of a UCITS? 33 Do you consider that the proposed limitations on the reference portfolio constitute

5/7 reasonable and adequate safeguards to ensure that the relative VaR method does not result in the UCITS taking excessive risk or leverage? 34 What additional safeguards (if any) do you consider necessary? None, if the additional safeguards are disclosed to and tested regularly by the regulator 35 Can the absolute VaR be considered as an appropriate way of measuring global exposure? Although it does not specifically state the amount of leverage (or true economic exposure) taken it shows how the portfolio value can change taking the inherent leverage into account in combination with market movements. 36 Do you consider that the proposed thresholds are suitable? Can you suggest other thresholds?, the 99% VaR, holding period 20 trading days, 20% absolute limit provides sufficient risk budget to exploit many if not most contemporary investment strategies 37 What are your views on the application of stricter criteria to difference types of asset classes e.g. bonds, equities? A case can be made to apply stricter criteria to differentiate acceptable risk levels across the asset types but this should be well defined. Intuitively one would expect tighter limits for bonds over equities but when looking at the details products like emerging bonds may show higher VaR numbers when compared to some equity strategies. It would make sense in any case however to have stricter risk criteria for Money Market products. 38 Do you consider the proposed safeguards, such as the use of appropriate additional risk management methods (stress-testing, CVaR) and the disclosure of the level of leverage, are sufficient safeguards when the absolute VaR method is used in the context of arbitrage strategies or complex financial instruments? No, not necessarily 39 Should UCITS using strategies that are potentially highly leveraged under the absolute VaR method be subject to specific marketing provisions, either at the level of the UCITS (minimum initial investment) or during the marketing process?, there can not be enough client information 40 Can you suggest alternative safeguards and/or requirements to avoid UCITS engaging in strategies which generate high levels of leverage? When Fund looses 3 months on a row, risk budget to be cut by 50% (say from index 100 to 50). When fund wins 3 months on a row budget to increase with 50% (from index 50 to 75), and when fund wins 3 months on a row again, another 33% increase restoring the funds initial risk budget

6/7 (from indexed 75 to 100). 41 Do you agree with the proposed method for calculating counterparty exposure? Daily and independent valuation of OTC s, requiring OTC s traded to be able to closed at any time, having ISDA s in place which provide for netting and daily collateralization in combination with selection criteria on the quality and standing of the counterparty all bring down the resulting current net exposure on the counterparty. As such it could be considered to drop the risk weightings. To completely drop the add-on however neglects the potential future mark-to-market exposure which can be incurred due to the rather practical aspects of closing out transactions, replacing them in the market place and the timely receipt of collateral called. An indicative 2 weeks is considered a reliable period to achieve this in reality. 42 Can you suggest an alternative method? In relation to Q41 it is therefore suggested to remain with a 10 days PFE factor which accounts for the frequency of collateral exchange and the general market movement such OTC type of instrument could occur. An average -of say the 5 largest European OTC traders- PFE factors could be employed as a pre-scribed minimum. 43 Do you agree with the approach for netting arrangements? Only if enforceable and legal documentation such as ISDA s are in place. 44 Do you consider that additional netting rules should apply? No 45 Do you agree with the proposed approach to agree a set of principles in relation to acceptable collateral to reduce counterparty exposure? Do you have alternative suggestions? We agree with agreeing a set of principles in relation to acceptable collateral to reduce counterparty exposure. What should emerge however is that in any case exposures are reduced and that a level playing field is created and respected. 46 Do you consider that rather than following principles based approach specific instruments that can be used as eligible collateral should be indentified? The importance is to create and respect a level playing field when reducing the exposures. As such a principle based approach should suffice. In addition, maybe it is an idea to exclude certain asset types (e.g. hedge funds, ABS, derivatives, etc) instead of appointing specific instruments. 47 Should collateral be UCITS compliant in terms of asset eligibility and diversification?, for client protection and to guard a level playing field. 48 Do you agree that collateral passed to a derivative counterparty should be include in the either the 5%/10% OTC counterparty limit or the 20% issuer concentration limit?

7/7 If legally a potential loss could incur to the UCITS when such OTC counterparty would default there is a case to include such loss of collateral in the issuer limit. The 20% issuer limit feels more appropriate since it covers both the OTC and max 10% single issuer scenario. 49 Do you have any other suggestions as to how such collateral passed should be treated? Legally ring fencing it in a separate account to both parties. 50 What areas of further work should be carried out with regard to this? The definition of the various possibilities under which such issuer exposures can be netted. 51 Do you agree with the proposal to abandon the use of the term sophisticated and non-sophisticated UCITS?, fully agree. 52 If you object to this proposal could you please provide reasons for this view? The distinction sophisticated / non sophisticated can be abandoned but it may be wise to hold on to the funds being required to conduct both the commitment approach (as to asses leverage and issuer concentrations) and VaR (as to achieve the sophisticated most risk sensitive/informativemarket risk measurement information). From a client perspective it could be argued that clients deserve the best risk management techniques available, regardless whether the fund follows a less or more sophisticated strategy. Clients want their money to be (risk) managed in their best interest and as such deserve the most risk sensitive information available which allows them best to make informed risk return decisions.